UPS Announces Significant Partnership Expansion with USPS
Get Alerts UPS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.3%
EPS Growth %: -6.3%
Join SI Premium – FREE
Primary Air Cargo Provider Status Awarded to UPS
ATLANTA--(BUSINESS WIRE)-- UPS (NYSE: UPS) today announced the company has been awarded a significant air cargo contract by the United Stated Postal Service (USPS). This award is effective immediately and greatly expands the existing relationship between the two organizations. Following a transition period, UPS will become the USPS’s primary air cargo provider and move the majority of USPS air cargo in the US.
“Together UPS and USPS have developed an innovative solution that is mutually beneficial and complements our unique, reliable and efficient integrated network,” said UPS Chief Executive Officer Carol B. Tome.
About UPS
UPS (NYSE: UPS) is one of the world’s largest companies, with 2023 revenue of $91.0 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. UPS also takes an unwavering stance in support of diversity, equity and inclusion. More information can be found at https://www.ups.com, about.ups.com and https://investors.ups.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401977055/en/
UPS Media Relations
404-828-7123
[email protected]
Source: UPS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
- Goldcana Announces Closing of Non-Brokered Private Placement for Gross Proceeds of $1,000,000
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share